Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-Bu-Mel Conditioning for Myeloid Disease Allo-HSCT
NCT04269811Phase 2Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2020
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, busulfan and melphalan in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Disease-Free Survival at 1 year. Started Jan 2020; status: completed.
02
Drugs
fludarabinebusulfanmelphalan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04269811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269811.